Intangible Assets

AYTU appears to have limited brand or IP-based pricing power because the provided profitability metrics show deeply negative ROIC and ROCE, which is more consistent with weak monetization than durable intangible advantage versus larger branded healthcare peers.

The company does not show evidence in the provided data of proprietary assets that would materially raise retention or margins over 5–10 years, unlike peers with stronger prescription brands, patented products, or regulated exclusivity.

Without visible evidence of durable regulatory exclusivity or differentiated clinical assets in the supplied metrics, intangible assets look replicable and therefore weak relative to peers.

Switching Costs

The negative ROIC and low asset turnover suggest customers are not locked into AYTU through high switching costs, because the business is not converting capital into durable economic returns better than peers.

In healthcare distribution or consumer health, switching costs are usually modest unless a company is embedded in workflows or formularies, and the supplied data does not indicate AYTU has that kind of peer-leading lock-in.

Compared with peers that benefit from physician habit, payer coverage, or institutional integration, AYTU shows no clear evidence of retention advantages that would sustain pricing power.

Network Effects

AYTU does not appear to operate a platform or marketplace where more users directly increase value for other users, so the core mechanics of network effects are absent.

The supplied metrics provide no sign of ecosystem-driven demand concentration or user interdependence, unlike peers in software or data networks where scale compounds defensibility.

Because there is no evidence of self-reinforcing adoption loops, network effects do not contribute meaningfully to moat durability versus peers.

Cost Advantage

Negative ROIC and ROCE indicate AYTU is not demonstrating a structural cost advantage that would allow it to underprice peers while still earning acceptable returns.

The low asset turnover suggests the company is not extracting superior productivity from its asset base relative to more efficient competitors, which weakens any claim to cost leadership.

Compared with scaled healthcare peers that can spread fixed costs across larger volumes, AYTU does not show evidence of a durable procurement, manufacturing, or distribution advantage.

Efficient Scale

AYTU does not appear to operate in a market structure where it controls a scarce niche at a scale large enough to deter entry, so efficient-scale protection looks limited.

The provided metrics do not show the kind of high-return, high-efficiency profile that typically accompanies a protected niche versus peers.

Compared with larger incumbents in healthcare, AYTU looks more exposed to competition because its scale does not appear sufficient to create a meaningful entry barrier or pricing umbrella.

Overall Score

AYTU’s moat appears weak versus peers because the supplied financial metrics show negative capital returns and no evidence of durable intangible assets, switching costs, network effects, cost advantage, or efficient-scale protection.